转移性前列腺癌伴基线轻中度白细胞减少患者对PSMA放射性配体治疗的耐受性
本研究纳入37例存在白细胞减少(白细胞计数<3.8×10^9/L)的转移性去势抵抗性前列腺癌(mCRPC)患者,接受中位3周期[177Lu]Lu-PSMA-617治疗。各周期及治疗结束时白细胞计数与基线相比无显著差异,27%患者CTCAE评分稳定、46%升高、27%降低。作者认为PSMA-RLT在CTCAE≥1级白细胞减少患者中可行,不应将白细胞减少患者一概排除。
要点
- 37例mCRPC伴白细胞减少患者接受中位3周期[177Lu]Lu-PSMA-617治疗。
- 各周期后白细胞计数与基线相比无显著差异(p均>0.05)。
- 治疗结束时27%患者CTCAE评分稳定、46%升高、27%降低。
核心结论
- 作者认为PSMA-RLT在CTCAE≥1级白细胞减少患者中可行,白细胞计数保持稳定且无显著RLT诱导的恶化。
- 作者认为不应将白细胞减少患者一概排除在PSMA-RLT之外。
研究设计与样本
- 本研究为单臂研究,纳入37例存在白细胞减少(白细胞计数<3.8×10^9/L)的mCRPC患者。
- 患者接受中位3周期[177Lu]Lu-PSMA-617治疗(范围1-9周期)。
- 试验注册号:Clinicaltrials.gov NCT04833517,注册日期2016年1月1日。
主要发现
- 第一周期后白细胞计数基线3.0±0.5 vs 随访3.4±1.4(×10^9/L),p=0.0921,无显著差异。
- 第二周期后白细胞计数基线3.1±0.4 vs 随访3.8±1.7,p=0.0509,无显著差异。
- 第三周期后白细胞计数基线3.1±0.4 vs 随访3.2±2.0,p=0.2929,无显著差异。
- 治疗结束时(不论周期数)白细胞计数基线3.0±0.5 vs 结束3.5±1.4,p=0.0684,无显著差异。
- 治疗结束后CTCAE评分:27%患者稳定,46%升高,27%降低。
临床怎么用
- 作者认为PSMA-RLT在CTCAE≥1级白细胞减少的mCRPC患者中可行。
- 作者认为不应将白细胞减少患者一概排除在PSMA-RLT之外。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Aim of this study was to analyze the safety of prostate-specific membrane antigen radioligand therapy (PSMA-RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC) with preexisting mild to moderate leukopenia (CTCAE ≥ 1). RESULTS: Thirty-seven mCRPC patients with preexisting leukopenia (leukocyte count < 3.8 × 109/L) were included in this study. Patients received a median of 3 cycles of [177Lu]Lu-PSMA-617 (range 1-9). No significant difference in leukocyte counts was observed between baseline and follow-up after each PSMA-RLT cycle: first cycle (3.0 ± 0.5 at baseline vs. 3.4 ± 1.4 at follow up [in × 109/L], p = 0.0921), second cycle (3.1 ± 0.4 vs. 3.8 ± 1.7, p = 0. 0.0509), and third cycle (3.1 ± 0.4 vs. 3.2 ± 2.0, p = 0.2929), respectively. Similarly, baseline and end of treatment values, irrespective of the number of administered cycles, did not reveal a significant difference (3.0 ± 0.5 vs. 3.5 ± 1.4, p = 0.0684). After the end of therapy, irrespective of the number of administered cycles, 27% patients remained stable in terms of CTCAE scoring, 46% changed to a higher score and 27% improved to a lower score. CONCLUSION: Although marked preexisting leukopenia is often considered a relative contraindication for PSMA-RLT, our findings indicate that PSMA-RLT is feasible in patients with leukopenia of CTCAE grade ≥ 1. In our cohort, leukocyte counts remained stable without significant RLT-induced deterioration. Therefore, patients with leukopenia should not be categorically excluded from receiving PSMA-RLT. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT04833517, registered 01.01.2016.
引用
- Bastian MB, Speicher T, Blickle A, et al. Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia. EJNMMI Res. 2025. PMID: 40619537. doi:10.1186/s13550-025-01280-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。